References for this Review were identified through a search of PubMed and the Cochrane Library for original research and reviews, with no date or language restrictions, on Aug 1, 2015. We did not intend to do a systematic review of the literature with evidence grading. No inclusion or exclusion criteria were used. Instead, we selected articles that were most relevant to the subheadings used in this Review. We searched for original research and reviews using the terms “respiratory syncytial
ReviewLower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics
Introduction
Respiratory syncytial virus (RSV) bronchiolitis contributes greatly to mortality in children under 5 years of age,1 and has implications for long-term respiratory health.2 Nearly all children in the world will be infected with RSV by 2 years of age.3
Several evidence-based guidelines for the management of bronchiolitis exist, with differing recommendations, but all agree on supportive management in the inpatient setting. A guideline published by the American Academy of Pediatrics4 reported insufficient evidence for any intervention except respiratory support and hydration. In view of the paucity of therapeutic alternatives, it is essential to understand the existing challenges to the development of prevention and treatment options for RSV.
Section snippets
Burden of disease
In the USA, RSV is the leading cause of hospital admission in children under 1 year of age, causes about 150 000 hospital admissions per year in children under 2 years of age, and accounts for 18% of all emergency department visits in children under 5 years of age.5, 6, 7 Beyond the substantial disease burden during acute infection, evidence suggests that RSV bronchiolitis plays a causal part in the development of recurrent wheeze, and is associated with the development of asthma and subsequent
Clinical management: less is more
Bronchiolitis is a variable but usually self-limiting disease, and it is estimated to resolve in 90% of children about 21 days after symptom onset.23, 24 However in the case of severe disease (defined by respiratory distress or dehydration) children need to be managed with intravenous fluids and supplemental oxygen as inpatients.
The American Academy of Pediatrics (AAP) bronchiolitis guideline4 restricts the use of therapeutic interventions that are not evidence based. Moreover, the Cochrane
New therapeutics
RSV is a negative-sense single-stranded RNA virus encoding 11 proteins. RSV mainly infects the ciliated airway epithelial cells of the respiratory tract and causes both damage and inflammation of the bronchioles. Two surface proteins (G and F) play a part in RSV binding and fusion respectively. The RSV viral envelope protein, SH (small hydrophobic), is an ion channel whereas the inner envelope is formed by the M (matrix) protein. Inside the viral envelope, four proteins make up the
Remaining challenges
Although the investment in RSV therapeutics has injected new hope in emerging RSV pharmaceuticals, challenges remain for their clinical development and implementation—namely absence of consensus on the most clinically relevant outcomes, the definitions of clear target populations, and barriers to drug access.
Consensus among academics, developers, and regulators is needed on clinical trial design, including identifying relevant endpoints and criteria of vaccine and therapy efficacy. In the
Conclusion
RSV bronchiolitis represents a worldwide health problem, with a substantial disease burden in children less than 5 years of age and 66 000–199 000 estimated deaths worldwide per year. Beyond the acute disease, RSV is implicated in the pathogenesis of recurrent wheeze and possibly in the development of asthma. Evidence-based guidelines offer no obviously effective therapeutic interventions, leaving the standard management of RSV bronchiolitis dependent on adequate hydration and respiratory
Search strategy and selection criteria
References (84)
- et al.
Determinants of asthma after severe respiratory syncytial virus bronchiolitis
J Allergy Clin Immunol
(2012) - et al.
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
Lancet
(1999) - et al.
Diagnosis, management, and prognosis of preschool wheeze
Lancet
(2014) - et al.
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
Lancet
(2010) - et al.
Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes
Paediatr Respir Rev
(2009) - et al.
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
Vaccine
(2013) - et al.
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)
Antiviral Res
(2008) - et al.
Strategic priorities for respiratory syncytial virus (RSV) vaccine development
Vaccine
(2013) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
Lancet
(2015)- et al.
Respiratory syncytial virus and recurrent wheeze in healthy preterm infants
N Engl J Med
(2013)
Risk of primary infection and reinfection with respiratory syncytial virus
Am J Dis Child
Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis
Pediatrics
Bronchiolitis-associated hospitalizations among US children, 1980–1996
JAMA
Direct medical costs of bronchiolitis hospitalizations in the United States
Pediatrics
The burden of respiratory syncytial virus infection in young children
N Engl J Med
The role of early life viral bronchiolitis in the inception of asthma
Curr Opin Allergy Clin Immunol
Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life
Thorax
Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis
Pediatr Infect Dis J
Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infants
Eur Respir J
Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes
J Infect Dis
Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma
Am J Respir Crit Care Med
Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy
BMC Pediatr
Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010–2011
J Infect Dis
Risk factors for bronchiolitis-associated deaths among infants in the United States
Pediatr Infect Dis J
Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age
Pediatrics
Duration of symptoms of respiratory tract infections in children: systematic review
BMJ
Frequent asymptomatic infections during a respiratory syncytial virus epidemic in a rural Kenyan household cohort
J Infect Dis
Bronchodilators for bronchiolitis
Cochrane Database Syst Rev
Glucocorticoids for acute viral bronchiolitis in infants and young children
Cochrane Database Syst Rev
Epinephrine for bronchiolitis
Cochrane Database Syst Rev
Evidence based guideline for the management of bronchiolitis
Aust Fam Physician
Guideline 91: Bronchiolitis in children, a national clinical guideline
Bronchiolitis in children: NICE guideline, draft for consultation
Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial
JAMA Pediatr
Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial
JAMA Pediatr
Hypertonic (3%) saline vs 0.93% saline nebulization for acute viral bronchiolitis: a randomized controlled trial
Indian Pediatr
SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis
Thorax
Diagnosis and management of bronchiolitis
Pediatrics
High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study
Eur J Pediatr
High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study
J Paediatr Child Health
Failure of high-flow nasal cannula therapy may delay intubation and increase mortality
Intensive Care Med
Failure of high-flow nasal cannula and delayed intubation: a new harmful sequence?
Intensive Care Med
Cited by (230)
Phytocompounds as a source for the development of new drugs to treat respiratory viral infections
2023, Studies in Natural Products ChemistryRespiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
2023, The Lancet Infectious DiseasesDrug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
2024, Nature CommunicationsRespiratory Syncytial Virus-Associated Hospitalizations in Children: A 10-Year Population-Based Analysis in Finland, 2008–2018
2024, Influenza and other Respiratory VirusesBacteria and viruses and their role in the preschool wheeze to asthma transition
2024, Pediatric Allergy and Immunology